Compare ACOG & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | HOWL |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 17.9M |
| IPO Year | 2024 | 2021 |
| Metric | ACOG | HOWL |
|---|---|---|
| Price | $8.76 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.00 | $5.00 |
| AVG Volume (30 Days) | 97.2K | ★ 555.9K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.58 | 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,220,275.00 | N/A |
| Revenue This Year | $139.22 | N/A |
| Revenue Next Year | $134.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $0.27 |
| 52 Week High | $9.99 | $2.23 |
| Indicator | ACOG | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 52.04 |
| Support Level | $5.27 | $0.40 |
| Resistance Level | $9.04 | $0.43 |
| Average True Range (ATR) | 0.83 | 0.05 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 62.52 | 32.73 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.